Ka-Man Venus Lai

This inventor holds 57 USPTO granted patents and 24 published patent applications, plus 10 CIPO patents and 25 EPO patents, primarily in Genetic Modification (CPC class A01K). Top assignees: Regeneron Pharmaceuticals, Inc., Regeneran Pharmaceuticals, Inc., Harvard College. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ka-Man Venus Lai. Retrieved from https://idiyas.com/inventor/ka-man-venus-lai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 57 (Patent Applications = 24)

% Patents Active = 100.0

CIPO Patents = 10 (Patent Applications = 10)

EPO Patents = 25 (Patent Applications = 33)

Average Co-Inventor Count = 5.1

ph-index = 9

Forward Citations = 292(Granted Patents)

Forward Citations (Not Self Cited) = 158(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Tarrytown, NY (US) (2013 - 2021)
San Francisco, CA (US) (2019 - 2022)
Seattle, WA (US) (2020 - 2024)

Company Filing History:

53 out of 1,482

Regeneron Pharmaceuticals, Inc.

patents

4 out of 49

Regeneran Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Humanized Proteins

Genome Editing

Nuclease-Mediated Assembly

Rodent Models

Antigen-Binding Proteins

Fibrillin-1 Mutations

Mood Disorders

Prostate Cancer

CD3 Complex

C9ORF72 Locus

Stem Cells

Paired Guide RNAs

57 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12677813 - GENETICALLY MODIFIED MICE HAVING A HUMANIZED PROGRAMMED CELL DEATH 1 GENE (2026-07-14),

2. 12637698 - METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAS (2026-05-26),

3. 12471579 - MOUSE MODEL OF DITRA DISEASE AND USES THEREOF (2025-11-18),

4. 12419282 - Non-human animals expressing humanized CD3 complex (2025-09-23),

5. 12369570 - Humanized IL-15 animals (2025-07-29),

6. 12342801 - Methods for producing antigen-binding proteins against foreign antigens (2025-07-01),

7. 12089575 - Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins (2024-09-17),

8. 12065661 - Genetic modification of rats (2024-08-20),

9. 12037596 - Targeted modification of rat genome (2024-07-16),

10. 11937587 - Non-human animals expressing humanized CD3 complex (2024-03-26),

11. 11932859 - Nuclease-mediated DNA assembly (2024-03-19),

12. 11820997 - Methods and compositions for the targeted modification of a genome (2023-11-21),

13. 11730150 - Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy (2023-08-22),

14. 11697828 - Methods and compositions for targeted genetic modification using paired guide RNAs (2023-07-11),

15. 11684050 - Non-human animals having a humanized programmed cell death 1 gene (2023-06-27),

Sure, I can help with that. Let's start with the article structure. Here's what we'll cover:

Title: The Innovative Work of Inventor Ka-Man Venus Lai

Introduction: Brief overview of Ka-Man Venus Lai and his contributions

Latest Patents: Description of his two latest patents

Career Highlights: Summary of his work at Regeneron Pharmaceuticals, Inc.

Collaborations: Mention of his coworkers David M. Valenzuela and David Frendewey

Conclusion: Wrap up his achievements and impact

Let's begin with the content for each section. Shall we proceed with the article?

Profile summary based on public USPTO records.